China Cord Blood Corp Revenue Chart (NYSE:CO)
$12.86 $0.32 (2.55%) CO stock closing price Aug 18, 2017 (Closing)
The latest 2017-Q4 China Cord Blood Corp revenue is 29.35M. Compare China Cord Blood Corp revenue chart with LHC revenue, Pharmerica revenue.
China Cord Blood Corp Revenue Chart
You can do annual as well as quarterly comparisons of China Cord Blood Corp net sales with its competitor companies like LHC, Pharmerica. Over the 5 year period China Cord Blood Corp revenue in 2017 was highest at 110.41M. In the latest quarter, CO revenue 2017-Q4 has changed from 28.93M to 29.35M implying an increase of 1.45%.
China Cord Blood Corp Quarterly Revenue
* Past 5 years Range
|Max CO Revenue||$29.35M||Mar, 2017|
|Min CO Revenue||$18.15M||Jun, 2012|
China Cord Blood Corp Annual Revenue
* Past 5 years Range
|Max CO Revenue||$110.41M||Mar, 2017|
|Min CO Revenue||$84.71M||Mar, 2013|
China Cord Blood Corp Annual Revenue VS Peers
|China Cord Blood Corp Revenue||$110.41M||$102.82M||$102.45M||$92.15M||$84.71M|
|Cryo Cell International Revenue||----||$23.12M||$21.09M||$20.12M||$18.99M|
China Cord Blood Corp Stock Articles
China Cord Blood Corp News
Revenue or net sales is the total amount of money that a company brings in through its various business activities before any costs or expenses are deducted. Revenue is also known as the topline or net sales or gross income. Revenue is for a specific period of time and appears as the "top line" in an income statement. By subtracting the costs or expenses from China Cord Blood Corp topline, we arrive at the bottom line for the company. Growing revenues over a period of time generally indicate that the company is in good health, however other factors need to be factored. Revenue can be calculated in two ways based on the type of accounting followed: accrual accounting or cashflow accounting. It is useful to compare China Cord Blood Corp revenue with peers Pharmerica topline, Gentiva Health Services topline, Cryo Cell International topline; to see how the company is doing with respect to its peers.